We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Abbott (ABT) Stock Drops Despite Market Gains: Important Facts to Note
Read MoreHide Full Article
In the latest close session, Abbott (ABT - Free Report) was down 1.94% at $98.16. The stock trailed the S&P 500, which registered a daily gain of 0.58%. Meanwhile, the Dow experienced a rise of 0.49%, and the technology-dominated Nasdaq saw an increase of 0.45%.
Coming into today, shares of the maker of infant formula, medical devices and drugs had lost 7.6% in the past month. In that same time, the Medical sector lost 4.26%, while the S&P 500 gained 0.84%.
The upcoming earnings release of Abbott will be of great interest to investors. The company's earnings report is expected on October 21, 2026. It is anticipated that the company will report an EPS of $1.43, marking a 10% rise compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $12.91 billion, up 13.52% from the prior-year quarter.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $5.52 per share and revenue of $50.32 billion, indicating changes of +7.18% and +13.51%, respectively, compared to the previous year.
Investors should also pay attention to any latest changes in analyst estimates for Abbott. These revisions typically reflect the latest short-term business trends, which can change frequently. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. Abbott is holding a Zacks Rank of #2 (Buy) right now.
Looking at valuation, Abbott is presently trading at a Forward P/E ratio of 18.13. This expresses a discount compared to the average Forward P/E of 19.6 of its industry.
One should further note that ABT currently holds a PEG ratio of 1.86. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Products industry had an average PEG ratio of 1.77 as trading concluded yesterday.
The Medical - Products industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 161, placing it within the bottom 35% of over 250 industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Abbott (ABT) Stock Drops Despite Market Gains: Important Facts to Note
In the latest close session, Abbott (ABT - Free Report) was down 1.94% at $98.16. The stock trailed the S&P 500, which registered a daily gain of 0.58%. Meanwhile, the Dow experienced a rise of 0.49%, and the technology-dominated Nasdaq saw an increase of 0.45%.
Coming into today, shares of the maker of infant formula, medical devices and drugs had lost 7.6% in the past month. In that same time, the Medical sector lost 4.26%, while the S&P 500 gained 0.84%.
The upcoming earnings release of Abbott will be of great interest to investors. The company's earnings report is expected on October 21, 2026. It is anticipated that the company will report an EPS of $1.43, marking a 10% rise compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $12.91 billion, up 13.52% from the prior-year quarter.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $5.52 per share and revenue of $50.32 billion, indicating changes of +7.18% and +13.51%, respectively, compared to the previous year.
Investors should also pay attention to any latest changes in analyst estimates for Abbott. These revisions typically reflect the latest short-term business trends, which can change frequently. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. Abbott is holding a Zacks Rank of #2 (Buy) right now.
Looking at valuation, Abbott is presently trading at a Forward P/E ratio of 18.13. This expresses a discount compared to the average Forward P/E of 19.6 of its industry.
One should further note that ABT currently holds a PEG ratio of 1.86. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Products industry had an average PEG ratio of 1.77 as trading concluded yesterday.
The Medical - Products industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 161, placing it within the bottom 35% of over 250 industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.